The experts on your list may not be the ones your programme needs.
0 +
Years Experience
0 +
Experts
0 +
Disease Areas
23+ years supporting Medical Affairs, Marketing, and Product teams
Trusted by global pharma, biotech, and Medical Communications teams
Strong experience across autoimmune, respiratory, oncology, and rare diseases.
Deep regional expertise in Japan and China
why most KOL lists miss the mark
Most KOL lists are built for scale, not for your situation.
Standard KOL services score specialists against the same generic criteria, then filter down to your disease area.
The result is a list built to be defensible at scale, not one built to find who matters for your specific research question.
These services begin by identifying influential clinicians within a specialty using data sources built for scale: publications, citation counts, society roles, congress activity. A standard scoring model is then applied across every specialty, every disease area, and every client.
Their approach is efficient, and it lets services standardise across specialties and clients. But efficiency is the point — not identifying the optimum KOLs for your programme. A scoring model built to generalise will surface the same names every time. Your competitors are looking at those names too.
The names that surface are predictable. The names that do not are the problem. We start from a different question — not who is prominent within a specialty, but who is relevant to the decision you’re making.
Why it impacts your programme
The consequences surface later.
A list built on general prominence often looks credible on paper. The problems show up in use.
Advisory boards that generate little actionable insight. Engagement budgets directed at the wrong people. Regional expertise that never appears because it does not register in global datasets. Senior KOLs whose influence does not extend to the specific disease context your programme depends on.
When those decisions need defending internally, in governance meetings, launch planning, or Medical review, a list you cannot fully justify becomes a real problem.
What moves your programme forward
Expert intelligence built around the decision you're actually making.
Most identification stops at prominence.
Kendle Healthcare starts with your product, your mechanism, and the specific decisions your programme needs to support. Different starting point. Different scoring. Often, different people on the list.
The goal is not a longer list, or a faster one. It is the right experts for the decisions you are making, with a clear rationale for why they are there and how they should be engaged. Every project is led directly by experienced specialists.
Outputs are documented to withstand internal scrutiny, regulatory review, and governance sign-off.
Case Study
When the data itself is the obstacle.
A respiratory mechanism spanning multiple diseases — one of them SARS-CoV-2, which had generated 100x more publications than the others combined. A landscape where standard publication analysis would have surfaced the wrong experts entirely. Here’s how we found the ones that mattered — including a working group the client didn’t know existed.
Two ways we work
Testimonials
What our clients say
Let's talk about your expert landscape.
The right experts depend on the right question.